Invictus Medical receives NSF grant to develop NICU technology

Invictus Medical, a manufacturer of medical devices for the improvement of healthy development for newborns, has received a grant from the National Science Foundation (NSF) Phase II grant to further develop its noise attenuation technology.

"This noise attenuation technology is so important for infants in the NICU. The literature indicates that levels of noise found in these care areas can have short- and long-term health consequences," said George Hutchinson, Invictus Medical's Chief Technology Officer. "The American Academy of Pediatrics' guidelines are very rigorous. This technology actively attenuates noise in incubators while allowing the parents to still converse with their babies. This is so important for language skill development."

The grant gives a total of $735,000 to assist Invictus in completing the development of the noise attenuation technology, which is expected to be completed in 2018. "The impact this product is going to have on the health of preterm infants in the NICU and on their cognitive development is very important," said Dennis Kane, Invictus Medical's CEO. "Invictus is committed to help this vulnerable population and we're gratified that the NSF saw the potential this represents."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.